CCC
MDT icon

Crescent Capital Consulting’s Medtronic MDT Stock Holding History

Crescent Capital Consulting’s Portfolio MDT Stock Details MDT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$89K Buy
860
+500
+139% +$57.9K 0.01% 241
2021
Q3 		$44K Hold
360
– – 0.01% 323
2021
Q2 		$44K Buy
360
+33
+10% +$4.14K 0.01% 285
2021
Q1 		$38K Buy
327
+33
+11% +$3.87K 0.01% 301
2020
Q4 		$34K Buy
+294
New +$32.4K 0.01% 278

Other funds holding MDT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crescent Capital Consulting's MDT Position: Q4 2021 in Review

Crescent Capital Consulting increased its Medtronic (MDT) stake by 139% in Q4 2021, buying an estimated $57.9K and bringing the position to 860 shares worth $89K. The position accounts for 0.01% of the portfolio, ranked #241.

Crescent Capital Consulting first reported a position in MDT in Q4 2020 and has held it in 5 quarters since. 2,059 funds tracked by Wall St. Rank hold MDT as of Q4 2021.

  • Crescent Capital Consulting held 860 shares of Medtronic worth $89K as of Q4 2021.
  • Crescent Capital Consulting bought 500 Medtronic shares in Q4 2021, an estimated $57.9K.
  • Medtronic made up 0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #241 holding.
  • Crescent Capital Consulting first reported a position in Medtronic in Q4 2020 and has held it in 5 quarters since.
  • 2,059 funds tracked by Wall St. Rank held Medtronic as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.